Boston Lung Cancer Study (Molecular and Genetic Analysis of Lung Cancer)
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMassachusetts General Hospital
About this trial
Investigators use a genome-wide approach within a case-control design to identify SNPs that show evidence of association with lung cancer risk and survival.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
younger than 18 years old
Trial population
Lung cancer cases are recruited from Massachusetts General Hospital patient population. Cases come from Thoracic Surgery or Cancer Center. Healthy controls are no longer recruited.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Survival among patients at different stages of lung cancer and treatment will be measured using questionnaires along with medical chart data to monitor treatment and disease progression
Study lung cancer development in a case control study. We will look at three separate outcome measures specified below
Time frame
20 yearsSecondary outcomes
1
Overall survival
Measurement from time of diagnosis to death will be obtained
Time frame
20 years2
Progression-free survival
Time of diagnosis to disease progression (measured by metastasis)
Time frame
20 years3
Treatment toxicities
Effects on ECOG and physical sequelae from treatment (radiation, chemotherapy and other treatment modalities will be analyzed)
Time frame
20 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Massachusetts General Hospital
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov